ALK and non-small cell lung carcinoma: Compared with traditional chemotherapy, crizotinib significantly prolongs progression-free survival (PFS) and reduces treatment-related adverse events, thus improving both prognosis and quality of life in ALK-positive NSCLC patients (Solomon et al., 2014).